What Is Metastatic Prostate Cancer and How Does It Spread?

Metastatic prostate cancer is prostate cancer that has spread beyond the prostate gland to distant sites in the body, most commonly bone. It accounts for the vast majority of prostate cancer deaths, and while it is not curable in the traditional sense, treatments have improved dramatically in the past decade. The disease exists on a spectrum, from a handful of bone spots found at initial diagnosis to widespread involvement of the skeleton, lymph nodes, and sometimes organs like the liver or lungs, and the treatment approach depends heavily on where a man falls along that spectrum.

Where It Spreads and Why Bone Is the Primary Target

Roughly nine out of ten men with metastatic prostate cancer have disease in their bones. The spine, pelvis, ribs, and femur are the most frequent landing sites. Lymph nodes are the second most common, and a smaller share of men develop metastases in the liver, lungs, or other soft-tissue organs. The dominance of bone is not random. Prostate cancer cells carry surface receptors that respond to chemical signals released by cells inside bone. Bone cells produce a signaling molecule called CXCL12, and prostate cancer cells express its matching receptor, CXCR4. This molecular handshake essentially guides circulating tumor cells toward bone, where they latch on and begin to grow.

Once prostate cancer cells arrive in bone, they hijack the normal cycle of bone building and bone breakdown. Unlike many other cancers that dissolve bone, prostate cancer tends to trigger abnormal new bone formation, producing dense, hardened lesions visible on scans. These lesions weaken the structural integrity of bone despite looking thick on imaging, which is why fractures and spinal cord compression remain serious risks.

Visceral Metastases and What They Signal

Liver metastases deserve special attention because they are becoming more common and carry a worse prognosis than bone-only disease. Population estimates suggest that roughly 3 to 10 percent of men with metastatic castration-resistant prostate cancer have liver involvement at baseline, but that figure rises to 20 to 30 percent in men who have already been through multiple treatments.¹ Autopsy studies put liver metastasis prevalence at up to a quarter of men with advanced disease. Molecular profiling of these liver lesions shows they tend to have low androgen receptor activity and features of neuroendocrine differentiation, meaning they are less likely to respond to standard hormone-based therapies. The rising prevalence of liver metastases may partly reflect the success of newer hormonal drugs at controlling bone disease while inadvertently selecting for tumor clones that thrive elsewhere.

How It Is Found

For years, metastatic prostate cancer was staged with bone scans and CT imaging. These tools still have a role, but they miss a lot. A newer generation of PET scans that target prostate-specific membrane antigen (PSMA) has transformed detection. In a head-to-head comparison, PSMA-based PET identified 139 sites of metastatic disease in a group of patients, while conventional imaging found only 45.² When conventional imaging missed or was uncertain about a lesion, there was about a 72 percent chance the PSMA PET would pick it up. The reverse scenario, PSMA PET missing something conventional imaging caught, was extremely rare.

This matters for treatment decisions. Finding more metastases earlier can change whether a man is classified as having low-volume or high-volume disease, which in turn affects which therapies are offered and how aggressively they are combined.

The Hormone-Sensitive Stage and Upfront Combination Therapy

When metastatic prostate cancer is first diagnosed or first found to have spread, it is almost always still hormone-sensitive, meaning it depends on testosterone to grow. The foundation of treatment is androgen deprivation therapy (ADT), which has been the backbone of prostate cancer management for over eight decades.³ ADT drops testosterone to very low levels, starving the cancer of its primary fuel. But ADT alone is no longer considered adequate for metastatic disease.

Current guidelines recommend combining ADT with at least one additional agent. The strongest evidence now supports “triplet therapy,” which layers ADT with a potent androgen receptor blocker and the chemotherapy drug docetaxel. The ARASENS trial found that adding darolutamide to ADT plus docetaxel reduced the risk of death by about a third compared with ADT plus docetaxel alone, and it more than halved the risk of the cancer becoming resistant to hormone therapy.⁴ Time to pain progression and time to bone-related complications also improved.

Not every man receives triplet therapy. For those who are not candidates for chemotherapy due to frailty or other health issues, doublet therapy pairing ADT with an androgen receptor blocker like apalutamide, enzalutamide, or darolutamide remains effective. Network meta-analyses comparing these doublet options have found similar efficacy among the available agents for progression-free survival.⁵

When Hormone Therapy Stops Working

Eventually, metastatic prostate cancer adapts. Despite testosterone levels being suppressed to castrate range, the cancer finds ways to reactivate androgen signaling or bypass it entirely. At this point, the disease is reclassified as castration-resistant, and the treatment strategy shifts. Even within castration resistance, though, hormonal drugs can still work: switching from one androgen pathway inhibitor to another sometimes buys time, though the benefit is limited if the cancer has already progressed on a similar agent.

Chemotherapy with cabazitaxel has a defined role after docetaxel and after an androgen receptor blocker. In a randomized trial, cabazitaxel nearly doubled progression-free survival compared with switching to another hormonal agent in men who had already used one, with a median of 8 months versus 3.7 months.⁶ Cabazitaxel also works in cell lines that are resistant to docetaxel, and clinical case reports have confirmed responses even in men with extremely advanced disease, including visceral metastases and very high PSA levels.⁷

Radioligand Therapy Targeting PSMA

One of the biggest advances in recent years is lutetium-177 PSMA-617, a radioligand therapy that delivers radiation directly to cancer cells expressing PSMA. In the landmark VISION trial, adding this treatment to standard care in men with castration-resistant disease extended median overall survival from about 11 months to about 15 months and more than doubled progression-free survival.⁸ The therapy is well tolerated relative to chemotherapy, with dry mouth and fatigue among the most common side effects, though bone marrow suppression can occur.

The treatment works by binding to PSMA on the surface of prostate cancer cells and irradiating them from close range. Because PSMA is highly expressed on prostate cancer cells and minimally expressed on most normal tissues, the radiation is relatively focused. Men must first undergo a PSMA PET scan to confirm their tumors actually express the target; those with PSMA-negative disease are not candidates.⁹

PARP Inhibitors and the Role of Genetic Testing

About 20 to 25 percent of men with metastatic castration-resistant prostate cancer carry mutations in DNA damage repair genes, either inherited or acquired by the tumor.¹⁰ These mutations, particularly in BRCA2, BRCA1, and ATM, make cancer cells dependent on a backup DNA repair pathway. PARP inhibitors block that backup pathway, trapping the cancer in a lethal situation where it cannot fix its own DNA. Several PARP inhibitors are now approved for men with these mutations.

This is why genetic testing has become standard for men with metastatic prostate cancer. Guidelines recommend testing for inherited mutations in BRCA1, BRCA2, and other repair genes, as well as testing tumor tissue for these same alterations.¹¹ About 10 percent of metastatic castration-resistant tumors carry inherited repair gene mutations, and another roughly 5 percent show mismatch repair deficiency, which opens the door to immunotherapy with pembrolizumab.¹² Finding a BRCA2 mutation also has implications beyond the patient: it can inform family members about their own cancer risks, including breast and ovarian cancer in female relatives.

Why Immunotherapy Has Mostly Disappointed

Prostate cancer is generally considered an immunologically “cold” tumor. It has a low rate of mutations overall, which means fewer abnormal proteins for the immune system to recognize. The tumor microenvironment is actively immunosuppressive, with sparse T-cell infiltration and low expression of the PD-L1 protein that checkpoint inhibitors typically target.¹³ Large trials of checkpoint inhibitors like pembrolizumab and nivolumab in unselected prostate cancer populations have been largely negative.

The exceptions are the small subsets mentioned above: men with mismatch repair deficiency or certain CDK12 mutations can benefit from checkpoint blockade. There is ongoing research combining immunotherapy with PARP inhibitors, radioligand therapy, and other agents that might increase the cancer’s visibility to the immune system by generating more DNA damage or releasing tumor antigens. For now, though, immunotherapy is not a routine part of treatment for most men with metastatic prostate cancer.

Neuroendocrine Transformation and Treatment Resistance

One of the more alarming ways metastatic prostate cancer evolves is through lineage plasticity, a process where the cancer cells essentially change their identity. Under the selective pressure of potent androgen-blocking drugs like enzalutamide and abiraterone, some tumor cells stop behaving like prostate adenocarcinoma and take on features of small-cell neuroendocrine cancer.¹⁴ This transformed cancer no longer depends on androgen receptor signaling at all, which renders all hormone-based therapies ineffective.

Neuroendocrine prostate cancer arises from the original adenocarcinoma rather than as an entirely new cancer. It retains early genomic changes from the original tumor while acquiring new molecular features that drive growth independently of hormones. This transformation is associated with a loss of dependency on the normal survival signals that the original tumor relied on, leading to broad drug resistance.¹⁵ Treatment options for neuroendocrine prostate cancer are limited and typically involve platinum-based chemotherapy regimens borrowed from small-cell lung cancer treatment. Research into reversing this lineage switch is active, with early work exploring targets like NSD2 that may restore the cancer’s sensitivity to standard therapies.

Managing Bone Complications

Because bone is the dominant site of metastasis, skeletal complications are a constant concern. Fractures, spinal cord compression, and the need for radiation or surgery to stabilize bones are collectively called skeletal-related events, and preventing them is a treatment goal in its own right. Two bone-targeted agents are available: zoledronic acid and denosumab. In a large head-to-head trial, denosumab delayed the first skeletal-related event to a median of about 21 months compared with about 17 months for zoledronic acid.¹⁶

Both drugs carry their own risks. Jaw osteonecrosis is a rare but serious complication of either agent, and dental evaluation before starting treatment is recommended. Zoledronic acid can affect kidney function, while denosumab can cause low calcium levels. Pain from bone metastases is another major quality-of-life issue. Radium-223, an alpha-emitting radiopharmaceutical that homes to areas of active bone turnover, has shown pain responses in a majority of treated patients. In one study, about 59 percent of patients achieved a meaningful reduction in their worst pain scores, with those who completed a full course of treatment faring better than those who received fewer doses.¹⁷

When Only a Few Spots Spread

Not all metastatic prostate cancer looks the same on scans. Some men have just one to three or five metastatic sites, a state called oligometastatic disease. There is growing interest in treating these limited metastases aggressively with stereotactic ablative radiation (SABR), which delivers high doses of focused radiation to individual spots. In the ORIOLE trial, men treated with SABR had a 6-month progression rate of 19 percent compared with 61 percent in those who were simply watched.¹⁸ Median progression-free survival was not even reached in the SABR group during the follow-up period.

A systematic review of randomized trials confirmed that SABR improves progression-free survival in oligometastatic prostate cancer without excessive toxicity, though overall survival data remain immature.¹⁹ The concept is that eliminating a small number of resistant clones might delay progression of the broader disease and push back the need for systemic therapy changes. Not everyone agrees on how many metastases qualify as “oligo” or which patients benefit most, and larger trials are ongoing.

Cardiovascular Side Effects of Long-Term Treatment

Living longer with metastatic prostate cancer means living longer on treatments that carry their own health consequences. ADT in particular has metabolic effects that accumulate over time: reduced muscle mass, increased body fat, higher risk of diabetes, and elevated blood pressure.²⁰ Whether ADT directly causes heart attacks and strokes or merely raises the conventional risk factors that lead to them is still debated. Either way, cardiovascular disease is a competing cause of death in men with prostate cancer, and managing heart health alongside cancer treatment has become a recognized priority. Exercise programs, careful monitoring of blood sugar and cholesterol, and sometimes cardiology referrals are increasingly part of prostate cancer care.

Monitoring Beyond PSA

PSA (prostate-specific antigen) remains the most common blood test used to track metastatic prostate cancer, but it has blind spots. Some aggressive variants, particularly neuroendocrine-transformed tumors, produce little or no PSA even as the disease progresses. Circulating tumor DNA (ctDNA) is emerging as a complementary tool. By detecting tumor-derived DNA fragments in the bloodstream, ctDNA assays can track molecular response to treatment in ways PSA cannot. A recent study in men with castration-resistant disease receiving enzalutamide showed that ctDNA dynamics added useful information beyond PSA for monitoring treatment response.²¹ This approach is still primarily used in clinical trials and select academic centers, but it points toward a future where treatment decisions are guided by more granular molecular data.

Racial Disparities in Access to Targeted Therapy

Black men in the United States are diagnosed with prostate cancer at higher rates and more often present with advanced disease. When it comes to biomarker-directed therapy in the metastatic setting, disparities persist. A study of men with castration-resistant disease found that Black men were significantly less likely to receive matched targeted therapy based on their tumor’s molecular profile: about 34 percent of Black men received it compared with about 54 percent of white men.²² When Black men did receive targeted therapy, their response rates and survival were no different from white men’s. The gap, in other words, is in access and referral, not in biology. This finding underscores the importance of ensuring that genetic testing and tumor profiling reach all men with metastatic disease, regardless of demographics.

Bipolar Androgen Therapy

One of the more counterintuitive strategies being explored for castration-resistant disease involves flooding the cancer with testosterone rather than starving it. The rationale is that cancer cells adapted to extremely low testosterone may become vulnerable to sudden high doses. Bipolar androgen therapy alternates between supraphysiologic testosterone injections and continued chemical castration, creating rapid swings in hormone levels that may destabilize the cancer’s adapted survival machinery.²³

Early-phase trials have confirmed that high-dose testosterone can be administered safely to men with castration-resistant disease.²⁴ Genomic analysis of men receiving this treatment showed that androgen receptor alterations, a hallmark of castration resistance, decreased in the majority of patients whose circulating tumor DNA was tracked.²⁵ This is still an experimental approach, and it is not appropriate for all patients, but it illustrates how deeply the biology of treatment resistance is reshaping the field. The idea that the same hormone driving early prostate cancer could become a weapon against late-stage disease would have been heresy a generation ago.

The Gut Microbiome Connection

An unexpected area of research involves the gut microbiome’s influence on prostate cancer treatment. The composition of gut bacteria appears to affect how well ADT works, with certain microbial populations having immunostimulatory effects that support treatment response while others are immunosuppressive or even directly undermine hormone therapy.²⁶ In animal models, antibiotic-induced disruption of the gut microbiome led to an overgrowth of certain bacteria, increased gut permeability, and a rise in inflammatory signaling within tumors that promoted cancer growth and resistance to docetaxel.²⁷ Whether modifying the gut microbiome through diet, probiotics, or fecal transplant could improve outcomes for men with metastatic prostate cancer is an open question, but the biology is compelling enough that clinical trials are beginning to test the idea.